1[1]Boyle P,Autier P,Bartelink H,et al.European code against cancer and scientific justification:third version.Annals of Oncology,2003,14:994-996.
2[2]McLaughlin JR,Fields ALA,Mao Y,et al.Canadian cancer statistics 1999.NCIC.Toronto,1999.34-35.
3[3]Ries LAG,Eisner MP,Kosaru CI,et al.SEER cancer statistics review,1973-1997.NIH Pub,No.00-2789.USA:National Cancer Institute,2000,171-181.
4[4]Eline EH,Susanne CJP.Gielenb,et al.Progesterone receptors in endometrial cancer invasion and metastasis:development of a mouse model.The 2nd International Symposium on Progestins.Progesterone Receptor Modulators and Progesterone Antagonists,2003,68:795-800.
5[5]Immaculata DV,Gordon SH,Susan EH,et al.A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk.PNAS,2002,99:12263-12268.
6[6]Elit L,Hirte H.Novel strategies for systemic treatment of endometrial cancer.Exp Opin Invest Drugs,2000,9:1-23.
7[7]COSA-NZ-UK Endometrial Cancer Study Groups.Adjuvant medroxyprogesterone acetate in hight-risk endometrial cancer.Int J Gynecol,1998,8:387-391.
8[8]Martin-Hivsch PL,Jarvis G,Kitchener H,et al.Progestagens for endometrial cancer.Oxford (The Cochrane Library):Update Software,1999.1.
9[9]Macdonald RR,Thorgood J,Mason MK.A randomized trial of progestogens in the primary treatment of endometrial carcinoma.Br Obstet Gynecol,1988,95:166-174.
10[10]Vergote I,Kjorstad K,Abeler V.A randomized trial of adjuvant progestogen in early endometrial cancer.Cancer,1989; 64:1011-1016.
同被引文献19
1曹泽毅.中华妇产科学[M].北京:人民卫生出版社,2004.2170-2172.
2连利娟.林巧稚妇科肿瘤学[M].北京:人民卫生出版社,1996:406.
3Thigpen J T, Brady M F, Alvarez R D, et al. Oral medmxypmgestemne acetate in the treatment of advanced or recurrent endome trial carcinoma: a doseresponse study by the Gynecologic Oncology Group[J]. J Clin Oncol, 1999,17 (6) : 1736-1744.
4Kinster R W. Histological elects of progestins on hyperplasia and carcinoma in situ of the endometrium[J]. Cancer, 1959,12:1106-1122.
5Gotlieb W H, Beiner M E, Shalmon B, et al. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer [J]. Obstet Gynecol, 2003, 102(4): 718-725.
6COSA-NZ-UK Endometrial Cancer Study Groups. Adjuvant medroxyprogesterone acetate in hlght-risk endometrial cancer[Jj. Int J Gynecol, 1998, 8: 387-391.
7Ranirez P T,Fiumovitz M, Bodurka D C. Homonal therapy for themanagement of grade 1 endometrial adenocarcinoma a literature review [J]. Gynecol Oncol,2004, 95(1 ) : 133-138.
8Montz F J, Bristow R E, Bovicelli A, et al. Intrauterine progesterone treatment of early endometrial cancer[J]. Am J Obstet Gynecol,2002, 186(4) :651-657.
9Gotlieb W H, Beiner M E, Shalmon B, et al. Outcome of fertility sparing treatment with progestins in young patients with endometrial cancer[J]. Obstet Gyneco|, 2003, 102(4): 718 725.
